Pulmonary Arterial Hypertension Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pulmonary Arterial Hypertension stocks.

Pulmonary Arterial Hypertension Stocks Recent News

Date Stock Title
Nov 21 PFE Pfizer: High Dividend And Low Price Might Still Offset The Expanding Risks
Nov 21 PFE Optimism over global healthcare sector rises: Jefferies
Nov 21 PFE Major companies that are also popular short-selling stocks
Nov 21 PFE 5 Best Value Stocks With Discounted PEG to Boost Your Portfolio Return
Nov 21 PFE The Zacks Analyst Blog Highlights Adobe, Pfizer, Dollar General, Snap and Ryanair
Nov 21 PFE Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
Nov 21 PFE 2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
Nov 21 PFE EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia
Nov 21 PFE 2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years
Nov 20 PFE CDC warns of an imminent spike in COVID, flu cases
Nov 20 PFE 5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential
Nov 20 PFE Pfizer Appoints Cancer Research Head Chris Boshoff as New R&D Chief
Nov 20 PFE Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
Nov 20 PFE Pfizer names head of oncology as new R&D chief
Nov 20 PFE Pfizer Announces New Chief Scientific Officer and President, Research & Development
Nov 20 PFE Pfizer names oncology head Chris Boshoff as R&D chief
Nov 20 PFE Pfizer Names New R&D Chief
Nov 20 PFE Pfizer, under pressure to change, names oncology head as new R&D chief
Nov 20 PFE Is It Time to Sell Eli Lilly and Pfizer Stocks?
Nov 20 PFE European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
Pulmonary Arterial Hypertension

Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure within the arteries of the lungs. Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat. The condition may make it difficult to exercise. Onset is typically gradual.The cause is often unknown. Risk factors include a family history, prior blood clots in the lungs, HIV/AIDS, sickle cell disease, cocaine use, COPD, sleep apnea, living at high altitudes, and problems with the mitral valve. The underlying mechanism typically involves inflammation of the arteries in the lungs. Diagnosis involves first ruling out other potential causes.There is no cure. Treatment depends on the type of disease. A number of supportive measures such as oxygen therapy, diuretics, and medications to inhibit clotting may be used. Medications specifically for the condition include epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, macitentan, and sildenafil. A lung transplant may be an option in certain cases.While the exact frequency of the condition is unknown, it is estimated that about 1,000 new cases occur a year in the United States. Females are more often affected than males. Onset is typically between 20 and 60 years of age. It was first identified by Ernst von Romberg in 1891.

Browse All Tags